Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide plus ascorbic acid in myelodysplastic syndromes
2005-001321-28Phase 2Terminated
- Sponsor
- AISSM
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide and ascorbic acid in myelodysplastic syndrome (MDS), sponsored by AISSM. Started Jun 2005; status: terminated.
02
Drugs
arsenic trioxideascorbic acid
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2005-001321-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001321-28.